Thomas Lingelbach: So good so then €“ so first of all, let me start with your first question. Yes, you have seen that at the ACIP meeting we presented additional data, additional readout from our elderly cohort. We consider based on all interactions that we had to-date, hat our database with about 100 people in the above 65 years of age combined with the fact that we do not see any age dependence on our zero protection level levels to be sufficient for the full label. This is our current hypothesis, and this is based on all interactions to-date, as I said driven by two aspects, namely number one, that we have not seen an age dependence on our serological and immunological profile for the vaccine. And that we have 100 people with some being really, really old in this cohort.
So second, when we target risk, this is of course, I mean this is an excellent question. And so on the one hand side, we consider of course people who are going to areas where there is a high risk exposure to chikungunya infection. These are areas where you have either already existing outbreaks or a high risk for outbreaks. And these are primarily the tropical, subtropical areas. And this will be as part of the health economics analysis, this is of course will be further detailed and characterized and precise as part of the ACIP process.
Olga Smolentseva: That’s great. Thank you.
Thomas Lingelbach: You’re more than welcome, Olga.
Operator: Thank you. One moment for next question. Our next question comes from the line of Nick Hallatt from Goldman Sachs. Your line is open.
Nick Hallatt: Hi, there, it’s Nick on for Keyur. Thank you for taking my questions. Just a couple more on chikungunya. What’s your updated thoughts on potential PRV monetization there? And if you could give us an idea of pricing and potential benchmarks we should be thinking about. And then if I may have financial question, your €12 million annual savings from the restructuring, where should we be thinking about their impact on the P&L and would that be largely on SG&A? Thank you.
Thomas Lingelbach: Okay, so do you want to start?
Peter Buhler: Yes, I can start on the savings out of the resizing of the organization. So Nick essentially, I would say the vast majority of the reduction is going to be in the manufacturing space, but because that’s where we clearly see the significant €“ most significant reduction in workload as we stop COVID-19. So that’s where I think most of it will go.
Thomas Lingelbach: So of course, on the PRV coming back to your question around the PRV, there was a process around the PRV was a respective application that we will do as part of the completion of the submission for the BLA. And then once we have the confirmed eligibility we will get the PRV with the BLA approval, and of course, the company will start marketing this PRV as soon as we are getting closer to the PRV. Many or most companies in the past have had their PRV deals in the pocket before they actually got the PRV. And this is of course something that we will do and we try to do in a similar way, provided that everything goes according to plan and that we have set under the Fast Track and provided it all Fast Track conditions are being confirmed. We expect the PDUFA date in the second half next year. So, which will tell you a little bit also the timeline of potential PRV.
Nick Hallatt: That’s great. Thank you. And do you have that pricing?
Peter Buhler: Yes, you mentioned pricing. I mean, as I told you already when we met we are currently not €“ we are in the middle of the process around health, economic, then analysis, pricing, et cetera. So we do not want to interfere with this process and therefore, we are currently not in a position to comment on pricing.
Nick Hallatt: Okay. Sounds good. Thank you very much.
Peter Buhler: You’re welcome.
